Of note, cancer treatment with certain drugs such as HDAC and kinase inhibitors, ATRA, and etoposide, which modulate MYB protein expression or activity as part of their anticancer activity, also revealed MYB-mediated resistance mechanisms. Here, HDAC9 is linked to cancer.